Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

NeoGenomics (NEO) Stock Plunges as CEO Abruptly Resigns and Co. Warns for Q1, Prompting Two Street Downgrades

Published 30/03/2022, 12:46 am
Updated 30/03/2022, 12:46 am
© Reuters.

NeoGenomics (NASDAQ:NEO) shares have collapsed 29% in pre-open trading Tuesday after announcing that CEO Mark Mallon will be stepping down from the top role and the board. In addition, the company said it now sees first-quarter revenue below the low end of its prior guidance of $118 - $120 million and EBITDA for the quarter below the low end of its previous guidance of $(15) - $(12) million. The larger loss was driven by higher than anticipated Clinical Services cost of goods sold. NeoGenomics also withdrew its 2022 annual financial guidance.

While the company said the CEO's departure was mutually agreed upon and not due to any disagreements, inappropriate action, or violation, the news took Wall Street by surprise. Two Wall Street analysts downgraded the shares following the announcement.

Stephens analyst Mason Carrico downgrades shares to Equal-weight from Overweight on "increased near-term uncertainty" following the CEO news, headwinds in the base business, and depressed margins. Carrico said while he may be downgrading shares near a bottom, he expects the stock to "languish" over the next year. He cut his price target to $16 from $34.

BofA Securities analyst Derik de Bruin cut shares to Hold from Buy with a new price target of $18 following the news. The analyst lowered FY22/23 revenue forecasts while increasing their net loss per share assumptions. After speaking with management, they indicated some incremental COVID-19 headwinds in the first quarter, and test volumes have not bounced back. Management is unsure why but sees this as more of a NEO-specific issue than an industry-wide one.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.